AbbVie received FDA approval for an ultra-rare blood cancer antibody-drug conjugate it acquired through its $10.1 billion buyout of ImmunoGen. The approval brings another asset from the ImmunoGen transaction into active commercial and lifecycle planning for AbbVie’s hematology portfolio. The approved ADC targets an aggressive ultra-rare malignancy, extending the deal’s impact beyond pipeline transfer into regulatory and market entry outcomes. The approval also highlights the strategy of combining large-scale acquisitions with continued development work on specific programs that can reach regulatory endpoints. For investors, the move signals that AbbVie’s ImmunoGen integration is producing label events rather than remaining confined to discovery-stage progress, tightening the connection between M&A activity and near-term regulatory timing.